logo

For the Inventor, By the Inventor

Modiin, Israel

Vascular Biogenics Ltd.


USPTO Granted Patents = 46

% Expired Patents = 65.2



Trademarks = 3

Forward Citations = 454

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Eyal Breitbart (26 out of 29 patents)

silverMedal Dror Harats (24 out of 31 patents)

bronzeMedal Gideon Halperin (19 out of 20 patents)

4.  Eti Kovalevski-Ishai (16 out of 17 patents)

5.  Niva Yacov (13 out of 14 patents)

6.  Jacob George (11 out of 16 patents)

7.  Itzhak Mendel (10 out of 12 patents)

8.  Erez Feige (8 out of 9 patents)

9.  Shoshana Greenberger (8 out of 11 patents)

10.  Livnat Bangio (7 out of 7 patents)

11.  Naamit Sher (5 out of 5 patents)

12.  Andrea Leubitz (4 out of 5 patents)

13.  Yaniv Salem (4 out of 6 patents)

14.  Nira Bloom (4 out of 4 patents)

15.  Michael R Peled (4 out of 25 patents)


Core Competencies:
Angiogenesis
Oxidized Lipids
Glioblastoma
Endothelial Cells
Atherosclerosis
Phospholipids
Polynucleotide Constructs
Anti-Angiogenic Agents
Fibrosis Treatment
Inflammatory Diseases
Cancer Therapy
Promoters

46 patents:

1. 11697682 - Motile sperm domain containing protein 2 antibodies and methods of use thereof (2023-07-11),
2. 11191848 - Methods of inducing responsiveness to anti-angiogenic agent (2021-12-07),
3. 10464957 - Oxidized lipids and methods of use thereof (2019-11-05),
4. 10383954 - Methods of inducing responsiveness to anti-angiogenic agent (2019-08-20),
5. 10369196 - Compositions and methods for treating glioblastoma GBM (2019-08-06),
6. 10206936 - Oxidized lipids and treatment or prevention of fibrosis (2019-02-19),
7. 10022388 - Oxidized lipids and treatment or prevention of fibrosis (2018-07-17),
8. 9968622 - High-purity phospholipids (2018-05-15),
9. 9771385 - Oxidized lipids (2017-09-26),
10. 9682154 - Methods of inducing responsiveness to anti-angiogenic agent (2017-06-20),
11. 9567605 - Methods for use of a specific anti-angiogenic adenoviral agent (2017-02-14),
12. 9403887 - Endothelial cell-specific polynucleotides and use thereof (2016-08-02),
13. 9254297 - Formulations and dosage forms of oxidized phospholipids (2016-02-09),
14. 9206206 - Oxidized lipid compounds and uses thereof (2015-12-08),
15. 9200056 - FAS-chimera adenovirus vector (2015-12-01),
Company Overview
Vascular Biogenics Ltd., based in Modiin, Israel, specializes in innovative therapeutic solutions targeting various vascular-related conditions. The company focuses on the development of oxidized lipids and anti-angiogenic agents, particularly for the treatment of glioblastoma and atherosclerosis. Their research encompasses endothelial cell-specific promoters and phospholipid formulations, aiming to address issues related to fibrosis and other vascular diseases through advanced polynucleotide constructs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Vascular Biogenics Ltd. USPTO Patent Assignee Logo
46 Patents

#1 in Modiin

#116 in Israel

#15,122 in the World

Modiin, IL
Modiin, Israel

Vascular Biogenics Ltd.

Forward Citations = 454

25 inventors:

goldMedal Eyal Breitbart (26 out of 29 patents)

silverMedal Dror Harats (24 out of 31 patents)

bronzeMedal Gideon Halperin (19 out of 20 patents)

4.  Eti Kovalevski-Ishai (16 out of 17 patents)

5.  Niva Yacov (13 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vascular Biogenics Ltd.. Retrieved from https://idiyas.com/company/vascular-biogenics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…